Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Merck Products Give Ono Pharma Renewed Life In Japan

This article was originally published in PharmAsia News

Executive Summary

TOKYO - Ono Pharma's drug portfolio is "going from maturity to decline," according to a Bank America Merrill Lynch analyst, but there are signs that in-licensed products from Merck, particularly antiemetic Emend (aprepitant), could bring new life to the company

You may also be interested in...



Emerging Views On Emerging Markets: Bank of America Merrill Lynch Global Healthcare Conference

In this periodic feature, PharmAsia News listens in at major industry events to hear what senior executives have to say about Asia and other emerging markets. In our last profile, we sat in on the recent Morgan Stanley Global Healthcare Conference in New York ('Emerging Views On Emerging Markets: Morgan Stanley Global Healthcare Conference,' PharmAsia News, Sept. 22, 2011). For this profile, we zoom in on the Bank of America Merrill Lynch Global Healthcare Conference, held Sept. 15-16 in London.

Emerging Views On Emerging Markets: Bank of America Merrill Lynch Global Healthcare Conference

In this periodic feature, PharmAsia News listens in at major industry events to hear what senior executives have to say about Asia and other emerging markets. In our last profile, we sat in on the recent Morgan Stanley Global Healthcare Conference in New York ('Emerging Views On Emerging Markets: Morgan Stanley Global Healthcare Conference,' PharmAsia News, Sept. 22, 2011). For this profile, we zoom in on the Bank of America Merrill Lynch Global Healthcare Conference, held Sept. 15-16 in London.

Ono Teams Separately With Onyx And Concordia To Continue Its In-Licensing Oncology Expansion

TOKYO - Ono Pharmaceutical has signed separate licensing agreements with Onyx and Concordia for oncology products, deals which the company said has caused it to lower its yearly forecast due to higher than expected in-licensing payments

Related Content

UsernamePublicRestriction

Register

ID1131161

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel